elranatamab
pfizer
['magnetismm-3', 'mmsm', 'multiple myeloma', 'elranatamab']
watch: mohamad mohty, md, phd, discusses extended follow-up from cohort a of the phase 2 magnetismm-3 trial of elranatamab in patients with relapsed/refractory multiple myeloma. #eha2023 #mmsm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.